VKTX Quote, Financials, Valuation and Earnings

Eli Lilly and has a net margin of -- compared to Viking Therapeutics's net margin of 8.48%. Viking Therapeutics's return on equity of -- beat Eli Lilly and's return on equity of 66.4%.

Viking Therapeutics has a consensus price target of $110.00, signalling upside risk potential of 159.74%. On the other hand Eli Lilly and has an analysts' consensus of $984.05 which suggests that it could grow by 23.68%. Given that Viking Therapeutics has higher upside potential than Eli Lilly and, analysts believe Viking Therapeutics is more attractive than Eli Lilly and.

Viking Therapeutics has a beta of 0.884, which suggesting that the stock is 11.566% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.409, suggesting its less volatile than the S&P 500 by 59.07%.

Viking Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.65% to investors and pays a quarterly dividend of $1.30 per share. Viking Therapeutics pays -- of its earnings as a dividend. Eli Lilly and pays out 77.65% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Viking Therapeutics quarterly revenues are --, which are smaller than Eli Lilly and quarterly revenues of $11.4B. Viking Therapeutics's net income of -$24.9M is lower than Eli Lilly and's net income of $970.3M. Notably, Viking Therapeutics's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 86.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viking Therapeutics is -- versus 17.61x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of -- compared to Viking Therapeutics's net margin of 18.95%. Viking Therapeutics's return on equity of -- beat Merck &'s return on equity of 29.26%.

Viking Therapeutics has a consensus price target of $110.00, signalling upside risk potential of 159.74%. On the other hand Merck & has an analysts' consensus of $128.73 which suggests that it could grow by 29.44%. Given that Viking Therapeutics has higher upside potential than Merck &, analysts believe Viking Therapeutics is more attractive than Merck &.

Viking Therapeutics has a beta of 0.884, which suggesting that the stock is 11.566% less volatile than S&P 500. In comparison Merck & has a beta of 0.393, suggesting its less volatile than the S&P 500 by 60.746%.

Viking Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 3.14% to investors and pays a quarterly dividend of $0.81 per share. Viking Therapeutics pays -- of its earnings as a dividend. Merck & pays out 2039.73% of its earnings as a dividend.

Viking Therapeutics quarterly revenues are --, which are smaller than Merck & quarterly revenues of $16.7B. Viking Therapeutics's net income of -$24.9M is lower than Merck &'s net income of $3.2B. Notably, Viking Therapeutics's price-to-earnings ratio is -- while Merck &'s PE ratio is 20.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viking Therapeutics is -- versus 4.00x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -- compared to Viking Therapeutics's net margin of 25.23%. Viking Therapeutics's return on equity of -- beat Pfizer's return on equity of 4.63%.

Viking Therapeutics has a consensus price target of $110.00, signalling upside risk potential of 159.74%. On the other hand Pfizer has an analysts' consensus of $31.86 which suggests that it could grow by 19.16%. Given that Viking Therapeutics has higher upside potential than Pfizer, analysts believe Viking Therapeutics is more attractive than Pfizer.

Viking Therapeutics has a beta of 0.884, which suggesting that the stock is 11.566% less volatile than S&P 500. In comparison Pfizer has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.739%.

Viking Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.28% to investors and pays a quarterly dividend of $0.42 per share. Viking Therapeutics pays -- of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend.

Viking Therapeutics quarterly revenues are --, which are smaller than Pfizer quarterly revenues of $17.7B. Viking Therapeutics's net income of -$24.9M is lower than Pfizer's net income of $4.5B. Notably, Viking Therapeutics's price-to-earnings ratio is -- while Pfizer's PE ratio is 36.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viking Therapeutics is -- versus 2.56x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of -- compared to Viking Therapeutics's net margin of 37.71%. Viking Therapeutics's return on equity of -- beat Vertex Pharmaceuticals's return on equity of -2.89%.

Viking Therapeutics has a consensus price target of $110.00, signalling upside risk potential of 159.74%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $493.61 which suggests that it could grow by 20.93%. Given that Viking Therapeutics has higher upside potential than Vertex Pharmaceuticals, analysts believe Viking Therapeutics is more attractive than Vertex Pharmaceuticals.

Viking Therapeutics has a beta of 0.884, which suggesting that the stock is 11.566% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.364, suggesting its less volatile than the S&P 500 by 63.631%.

Viking Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viking Therapeutics pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

Viking Therapeutics quarterly revenues are --, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. Viking Therapeutics's net income of -$24.9M is lower than Vertex Pharmaceuticals's net income of $1B. Notably, Viking Therapeutics's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 25.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viking Therapeutics is -- versus 10.00x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.